Vanguard Group Inc. Trims Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

Vanguard Group Inc. cut its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 4.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,394,731 shares of the company's stock after selling 185,832 shares during the period. Vanguard Group Inc. owned approximately 7.22% of Health Catalyst worth $31,071,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Fox Run Management L.L.C. purchased a new stake in shares of Health Catalyst during the 4th quarter valued at approximately $216,000. American Century Companies Inc. raised its position in Health Catalyst by 1.8% in the fourth quarter. American Century Companies Inc. now owns 710,481 shares of the company's stock valued at $5,023,000 after purchasing an additional 12,682 shares during the period. Quantbot Technologies LP purchased a new stake in Health Catalyst in the fourth quarter valued at $29,000. Virtu Financial LLC acquired a new position in shares of Health Catalyst in the 4th quarter valued at $110,000. Finally, Palogic Value Management L.P. purchased a new position in shares of Health Catalyst during the 4th quarter worth $2,262,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Health Catalyst

In other Health Catalyst news, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the transaction, the general counsel now directly owns 160,437 shares in the company, valued at $729,988.35. This represents a 7.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the business's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $5.76, for a total transaction of $30,003.84. Following the sale, the chief operating officer now owns 86,044 shares of the company's stock, valued at $495,613.44. This represents a 5.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,588 shares of company stock valued at $225,906 over the last quarter. 2.50% of the stock is owned by insiders.

Health Catalyst Stock Up 2.4 %

NASDAQ HCAT traded up $0.09 on Friday, hitting $3.84. 465,545 shares of the stock were exchanged, compared to its average volume of 613,233. Health Catalyst, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $9.24. The company has a 50-day moving average price of $4.50 and a 200-day moving average price of $6.40. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market cap of $269.61 million, a PE ratio of -2.84 and a beta of 1.43.

Analyst Upgrades and Downgrades

HCAT has been the topic of a number of recent analyst reports. Citigroup decreased their target price on shares of Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. Canaccord Genuity Group lowered their price objective on shares of Health Catalyst from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, January 21st. KeyCorp cut their target price on Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday. Stephens lowered their price target on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday, March 6th. Finally, Evercore ISI lowered Health Catalyst from an "outperform" rating to an "inline" rating in a research note on Wednesday, April 9th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.36.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.